Icosavax — Investor Presentation (April 2022)
41 slides from Icosavax's investor presentation, Apr 25, 2022
Slide 1: The world needs better vaccines. Corporate Overview April 2022
The world needs better vaccines. We’re striving to create them. CORPORATE OVERVIEW | APRIL 2022 Exhibit 99.1
Slide 2: Forward looking statements
Forward looking statements Statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on the company’s current beliefs and expectations and include, but are not limited to: the company’s goal to p
Slide 3: What if a single vaccine could protect against multiple respiratory infections?
RSV hMPV COVID-19 Flu What if a SINGLE VACCINE could protect you from multiple viral respiratory infections? AND LAST BEYOND A SINGLE SEASON AND COVER EMERGING VARIANTS AND LIMIT UNWANTED SIDE EFFECTS
Slide 4: Significantly reduce hospitalization and death
AND significantly reduce hospitalization and death? U.S. hospitalizations and deaths per year (older adults) ^ Extrapolated from six months data to an annualized figure. CDC, RSV Trends and Surveillance; CDC Health Alert network, alert CDCHAN-00443; Sieling et al 2021, Influenza Other Respiratory Vi
Slide 5: Especially in the more vulnerable older adult population
Especially in the MORE VULNERABLE OLDER ADULT POPULATION RISK Maternal immunization Infant immunization Older adult immunization Waning immunity with time creates risk for infection and hospitalization PROTECTING THE WORLD’s >600 MILLION* OLDER ADULTS CAN HELP THEM ACHIEVE THEIR FULL LIFESPAN *Aged
Slide 6: A new approach focused on virus-like particles (VLPs)
We’re aiming to do just that—with a new approach focused on VIRUS-LIKE PARTICLES (VLPs) From technology born out of a collaboration between the Gates Foundation and the University of Washington’s Institute for Protein Design, Icosavax emerged with a vision to create the best vaccines in the world Ou
Slide 7: VLPs may offer potential benefits
VLPs may offer one or more of these POTENTIAL BENEFITS Magnitude of response When compared to existing modalities, WE BELIEVE OUR VLP TECHNOLOGY HAS THE POTENTIAL TO IMPROVE UPON: Breadth of coverage Durability to counter immunosenescence that can occur in the elderly greater degree of protection ag
Slide 8: VLPs have multiple potential benefits (cont'd)
HPV-16 (similar results for HPV-18) Yr 10 Yr 5 VLPs have MULTIPLE POTENTIAL BENEFITS (cont’d) TECHNOLOGY TYPE FOLD CHANGE YA NTS/HCS* EFFICACY (%) ORIGINAL STRAIN* VLP† SK Bioscience ~6 TBD Bavarian Nordic ~12 TBD Soluble protein/micelle ~4 96 mRNA ~3-4 94-95 Ad vector ~1 62-90 Potentially Higher Ma
Slide 9: VLPs may also allow for combination vaccines for older adults
RSV hMPV COVID-19 Flu PEDIATRICS Combination vaccines have been available for years – up to 6 in 1 shot OLDER ADULTS The time has come for combination vaccines for older adults - VLPs are an ideal modality to succeed with this vision as naturally occurring VLPs have already been utilized as combinat
Slide 10: VLPs mimic the structure of real viruses
Unlike soluble antigens, VLPs mimic the STRUCTURE of real viruses Natural virus Soluble antigen VLP-based antigen Traditionally manufactured or mRNA-derived
Slide 11: Superior immune response from VLPs
Because the body “sees” VLPs as viruses, the result may be a SUPERIOR IMMUNE RESPONSE Weaker activation signals and lower levels of antibodies lead to a weaker immune response. Multivalent antigen display enables cross-linking of B-cell receptors in the lymph nodes, potentially leading to a stronger
Slide 12: Multiple mechanisms underpin the immune response to VLPs
MULTIPLE MECHANISMS may underpin the anticipated robust immune response to VLPs Internalized VLPs VLP Improved antigen uptake and presentation by APCs Efficient trafficking to lymph nodes Enhanced cellular crosstalk Strong cross-linking of B cell receptors LYMPH NODE APC Naive T cell Activated CD4+T
Slide 13: VLPs proven safe and effective as vaccines; two Icosavax candidates in clinic
VLPs have already been PROVEN safe and effective as vaccines; two Icosavax candidates now in the clinic NATURALLY OCCURRING VLPs ARE UTILIZED IN VACCINES that have been in market and established for years Gomes et al 2018; Rappuoli and Serruto 2019; Sherwood et al 2020; Gara et al 2015; PATH Single-
Slide 14: Proprietary, 2-component, precision-designed VLP system
Our VLPs are produced via a PROPRIETARY, 2-COMPONENT, PRECISION-DESIGNED system IVX-121 IVX-241 FLU IVX-411 hMPV RSV SARS-CoV-2 FLU Trimeric protein genetically fused to target antigen Antigen properly folds to display neutralizing epitopes before assembly into VLP New antigen design capabilities al
Slide 15: Multiple manufacturing advantages
c c c c c Highly productive, flexible scalable system using standard recombinant protein (eg, mAb) production/purification methods Supply chain and capacity already exists globally Typical single-use bioreactor suite could produce ~100 million–2 billion doses/year* Can flex to respond to a pandemic
Slide 16: Major unmet needs with our VLP technology
We are pursuing major UNMET NEEDS with our VLP technology Bacterial Viral Challenging to vaccinate (100s of strains) Approved vaccines exist ~$5B in sales Approved vaccines exist ~$8B in sales No approved vaccines Respiratory vaccines are an emerging market: There are no approved vaccines for RSV or
Slide 17: Progressing multiple assets in the clinic
We are currently progressing MULTIPLE ASSETS in the clinic * Icosavax does not plan to pursue the IVX-121 RSV monovalent candidate as a standalone candidate for RSV in older adults, and plans to transition development to the IVX-A12 bivalent RSV/hMPV candidate following Phase 1. ^ Icosavax has world
Slide 18: RSV/hMPV Bivalent Vaccine Candidate (IVX-A12)
RSV/hMPV Bivalent Vaccine Candidate (IVX-A12) CONFIDENTIAL
Slide 19: IVX-A12 targets both RSV and hMPV
Our first combination vaccine candidate—IVX-A12—targets BOTH RSV and hMPV Found in 8% of US adults hospitalized for pneumonia where pathogen detected 16% likelihood of ICU admission, 5% likelihood of death Symptoms: Cough, fatigue, dyspnea, congestion, wheezing, fever RSV Found in 11% of US adults h
Slide 20: High neutralizing antibody titers may be key to better protection
Every log2 improvement in nAb titers believed to lead to a clinically relevant improvement in disease outcome Falsey, ResViNet, Malaga 2017 (data adapted for table on left); data from Falsey et al 2008, J Infect Dis; Walsh et al 2004; Falsey et al 2010 High neutralizing antibody (nAb) titers may be
Slide 21: IVX-121: Prefusion RSV-F protein may lead to higher titers
Graham et al 2015; Ruckwardt et al 2021 IVX-121 for RSV: Prefusion RSV-F protein may lead to higher neutralizing antibody titers Proof of concept Subunit (Ph1) Subunit Recombinant vector or mRNA VLP Companies & Technologies: mRNA DS-Cav1 Adult Neutralizing Titer GMFR ~7-10x Postfusion protein subuni
Slide 22: IVX-121: Clinical data support DS-Cav1 as improved prefusion F antigen
IVX-121 for RSV: Clinical data support DS-Cav1 as improved prefusion F antigen NIH DS-Cav1 Phase 1 study explored long-term immunogenicity and dosing in young adults (N=95) Reference point for Phase 1 portion of IVX-121 study 50, 150, 500 mcg +/- alum adjuvant Transient dose effect at week 4, margin
Slide 23: IVX-121: Phase 1/1b trial initiated September 2021
IVX-121 for RSV: Ph 1/1b trial initiated September 2021 Phase 1b revaccination Subset of Ph 1b OA cohort 12 months follow-up Revaccination at 12 months after initial Ph 1b dose Following the Phase 1/1b trial, we plan to combine IVX-121 with IVX-241 (our hMPV candidate) for further clinical developme
Slide 24: IVX-241 for hMPV: Prefusion stabilized F antigen selected
Icosavax has exclusively licensed rights to the prefusion stabilized F antigen incorporated into IVX-241 (except for one mRNA license that can be granted) IVX-241 for hMPV: Prefusion stabilized F hMPV/A antigen selected Similar to RSV, the critical hMPV F protein target undergoes a conformational ch
Slide 25: Safety and immunogenicity of bivalent formulations
Safety and immunogenicity of bivalent (RSV/hMPV) formulations Healthy young and older adults Constant RSV dosage level + multiple hMPV dosage levels 1- and 2-dose regimens +/- adjuvant Phase 2A DURATION Phase 1 Phase 2a IVX-A12 Ph 1 and 2 trials will plan to assess safety and immunologic non-interfe
Slide 26: Only company pursuing RSV and hMPV with the VLP modality
Icosavax is the only company pursuing RSV and hMPV with the VLP modality PRECLINICAL PHASE 1 PHASE 2 PHASE 3 VLP Subunit / Soluble Antigen Recombinant Vector GSK Prefusion RSV-F + ASO1 Pfizer Prefusion RSV-F + alum Janssen Adenovirus + soluble RSV-F Bavarian Nordic MVA RSV-F Live-Attenuated Meissa R
Slide 27: RSV vaccine potential to be recommended by policy makers
A vaccine against RSV has the potential to be recommended by policy makers, which could drive rapid coverage and uptake; a combination RSV+ vaccine may be preferred by vaccinators Policy makers and payors: Anticipated recommendations for a RSV vaccine in adults 18+ at risk and pregnant women 60+ ü ü
Slide 28: Covid-19 Vaccine Candidate (IVX-411)
Covid-19 Vaccine Candidate (IVX-411)
Slide 29: Potential endemic market opportunity
Potential endemic market opportunity There is value beyond the pandemic – future endemic landscape offers an opportunity Emergence of variant strains, reactogenicity and limited durability of current approaches have created gaps/need for additional vaccine modalities Expectations are for vaccines to
Slide 30: IVX-411 utilizes an RBD antigen for SARS-CoV-2
Spike glycoprotein “S-2P” RBD RBD nanoparticle vaccine IVX-411 utilizes a receptor binding domain (RBD) antigen for SARS-CoV-2 Piccoli et al 2020, Cell; Walls AC & Fiala B et al 2020, Cell RBD: Critical functional domain of spike protein responsible for interaction with ACE2 receptor ~90% of neutral
Slide 31: Study met primary safety and immunogenicity objectives
Study met primary safety and immunogenicity objectives: Phase 1 in primary setting (n = 84). 2 doses, 28 days apart: 5, 25, 125 ug IVX-411 dosage levels +/- adjuvant Phase 2 in booster setting (n = 84). 1 dose, 3-6 months after completion of primary regimen: 5, 25, 125 ug IVX-411 +/- adjuvant IVX-41
Slide 32: IVX-411 booster effect against wild-type and Omicron
25µg + adjuvant IVX-411 exhibited a booster immunogenicity effect against both wild-type and Omicron strains Administration of IVX-411 3-6 months following immunization with licensed mRNA or Adenoviral vector based vaccines resulted in a fold-rise of up to 5x or 7x vs. baseline for wild-type and Omi
Slide 33: SK Bio VLP data suggests possible lack of potency with IVX-411
Data from comparable SK Bio VLP technology suggests possible lack of potency with IVX-411 SK Bio and Icosavax licensed the same VLP technology in the COVID-19 field from University of Washington with very similar RBD antigens incorporated into their candidate vaccines: GBP510 and IVX-411 respectivel
Slide 34: Flu Program
Os) ICOSAVAX Flu Program
Slide 35: Unmet need for an influenza vaccine with improved efficacy
There is an unmet need for an influenza vaccine with improved efficacy, particularly in the older adult population * 2020-2021 flu vaccine effectiveness was not estimated due to low flu virus circulation during the 2020-2021 flu season; ** Interim vaccine effectiveness estimates, as of March 2022 So
Slide 36: Flu program initiated
Flu program initiated – another strategic component of our vision We plan to build a rapid production system capable of supporting seasonal flu, which we expect to also enhance our pandemic response capabilities Initial preclinical evaluation by NIH of precursor VLP molecule utilized hemagglutinin (
Slide 37: UW/NIH data: VLP display provided higher titers and broader response
UW/NIH data (precursor molecule): VLP display of antigens provided higher neutralizing titers and broader strain response Immunogenicity against vaccine-matched antigens Immunogenicity against historical H3N2 virus strains Adapted from Boyoglu-Barnum et al 2021, Nature In mice, ferrets (data shown)
Slide 38: In summary: Why Icosavax?
Os) ICOSAVAX In summary: Why Icosavax?
Slide 39: Executive Team, Scientific Advisory Board and Board of Directors
Executive Team Executive Team Adam Simpson Chief Executive Officer Doug Holtzman, Ph.D. MPH Chief Scientific Officer Niranjan Kanesa-thasan, M.D. MTMH Chief Medical Officer Tom Russo Chief Financial Officer Cassia Cearley, Ph.D. Chief Business Officer Elizabeth Bekiroğlu General Counsel Charles Rich
Slide 40: Developing VLP-based vaccines and combinations for older adults
Developing VLP-based vaccines and combinations, with vision of pan-respiratory vaccines for older adults Unique modality intentionally designed to mimic the structure of viruses to empower better immune response VLPs have multiple potential benefits—and offer multiple manufacturing advantages and at
Slide 41: Novel VLP technology with multiple near-term value inflection points
Novel VLP technology with multiple near-term value inflection points Candidate Indication IVX-121 RSV DP release CTA approval Ph 1 Initiated Phase 1/1b interim, topline data [Q2’22] Plan to transition development to IVX-A12 bivalent RSV/hMPV candidate IVX-A12 RSV/hMPV hMPV candidate selection Pre-IN